AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05113030 — intervention group
Intervention type: OTHER
Intervention: PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED
Description: Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
Study NCT05519007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Rinse Solution (NS)
Description: The surgical site will be irrigated with NS prior to closure,
Study NCT05519007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline irrigation
Description: The surgical site will be irrigated with Saline
Study NCT04842383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemp Oil
Description: Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
Study NCT04784559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Study NCT04784559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Study NCT04977258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill aerobic exercise without water intake
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
Study NCT04977258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise with water intake of a predetermined amount.
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
Study NCT04977258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise with water intake according to the desire to drink
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
Study NCT04784559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Study NCT04784559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Study NCT06583005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Coordinated Reset
Description: The Stanford CR glove is designed to administer vibrotactile coordinated reset stimulation, which consists of vibratory stimulation of the fingertips delivered in a specific pattern which is design to disrupt and normalize abnormal brain synchrony.
Study NCT05460702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Soluble immune checkpoints
Description: Blood collection from breast cancer patients with stage I-II
Study NCT05768854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate
Description: Administered per investigator discretion via intravenous (IV) infusion
Study NCT05768854 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Study NCT05768854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Study NCT05066906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Identifor assessment tool and Companion app
Description: Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management.
Study NCT05066906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to employment agencies
Description: Standard referral to employment agencies based on an individual's background, skillset, and preferences
Study NCT06488287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (brain stimulation)
Description: The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
Study NCT06488287 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Transcranial direct current stimulation (brain stimulation)
Description: The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
Study NCT05066906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to employment agencies
Description: Standard referral to employment agencies based on an individual's background, skillset, and preferences
Study NCT05193838 — intervention group
Intervention type: DRUG
Intervention: Allopurinol Tablet
Description: examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
Study NCT05560490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroFix Cartilage P Knee Implantation
Description: The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
Study NCT05492786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert
Description: Non-interruptive best practice alert in the electronic health record
Study NCT05492786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alert
Description: Non-interruptive best practice alert in the electronic health record
Study NCT05492786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salient alert features
Description: Larger alert header and body font size, use of different font colors and boldface
Study NCT05492786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-risk Text
Description: Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
Study NCT05492786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk factors
Description: Alert body indicates the top 3 factors contributing to the high risk
Study NCT05134415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor 1
Description: 2-week ad libitum use of the RELX ENDS tobacco flavor 1
Study NCT05134415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor 2
Description: 2-week ad libitum use of the RELX ENDS tobacco flavor 2
Study NCT05134415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor 1
Description: 2-week ad libitum use of the RELX ENDS menthol flavor 1
Study NCT05134415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor 2
Description: 2-week ad libitum use of the RELX ENDS menthol flavor 2
Study NCT05756582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prevalence of Latent Tuberculosis Infection
Description: The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
Study NCT05492643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Description: all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Study NCT05492643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Immunity
Description: the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
Study NCT05492643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humoral Immunity
Description: the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
Study NCT05492643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety
Description: all the 500 participants enrolled will undergo safety observation
Study NCT06438432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAIT
Description: The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
Study NCT05843669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guafenesin tablets
Description: During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
Study NCT05413720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: two additional blood samples specific to research
Description: proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
Study NCT05207891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention mattress
Description: The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
Study NCT05040633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))
Description: Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
Study NCT05040633 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))
Description: Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
Study NCT05484492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: demineralized and mineralized combination putty bone allograft
Description: Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
Study NCT05484492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: calcium phosphosilicate putty alloplast graft
Description: Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
Study NCT04873596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized dexmedetomidine
Description: parturient will receive nebulized 3ug/kg dexmedetomidine.
Study NCT04873596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized midazolam
Description: parturient will receive nebulized 0.2 mg/kg midazolam.
Study NCT06134037 — intervention group
Intervention type: DRUG
Intervention: Aminophylline
Description: Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
Study NCT05099835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
Study NCT05099835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolonacetonide
Description: triamcinolonacetonide stellate ganglion injection
Study NCT05203783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie Exercises
Description: McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension
Study NCT05040633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Exercise Therapy
Description: Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
Study NCT05040633 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Exercise Therapy
Description: Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
Study NCT05040633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Therapy
Description: Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
Study NCT05987865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.
Study NCT05071703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: * Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)
Study NCT05897892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clinical study on the mangrove sword bean food bar effect for older people
Description: The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
Study NCT05897892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clinical study on the mangrove sword bean food bar effect for older people
Description: The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
Study NCT05181124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coadministration of JP-1366 and aceclofenac
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Study NCT05181124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coadministration of JP-1366 and meloxicam
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Study NCT05181124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coadministration of JP-1366 and naproxen
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Study NCT05181124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single-dosing of JP-1366 in Korean and Caucasian
Description: An open-label, single-dosing, parallel design
Study NCT05325346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX-1005
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Study NCT05325346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VLX-1005
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Study NCT05325346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argatroban
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Study NCT05325346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Argatroban
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Study NCT06435923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-darigabat
Description: Oral capsule
Study NCT04920383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-202
Description: Various doses
Study NCT04920383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab KEYTRUDA®
Description: Varies
Study NCT05280600 — intervention group
Intervention type: OTHER
Intervention: Not applicable - non-interventional study
Description: Not applicable - non-interventional study
Study NCT05029102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
Study NCT05029102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
Study NCT05604781 — intervention group
Intervention type: DEVICE
Intervention: Symfony & Synergy IOL combination
Description: The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
Study NCT05203783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape Application
Description: Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day